Results 101 to 110 of about 57,075 (302)

Practice guidelines for the administration of buprenorphine for treating opioid use disorder.

, 2021
The Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder provides eligible US physicians, physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, and ...

core  

Trajectories of medication for opioid use disorder and their impact on HIV testing among people who inject drugs in India: A longitudinal assessment of clinic‐based data

Addiction, Volume 120, Issue 4, Page 745-755, April 2025.
Abstract Aims The aim of this study was to identify longitudinal trajectories of medication for opioid use disorder (MOUD) use throughout 1 year following MOUD initiation and to examine the association of trajectory membership with HIV testing among people who inject drugs in India.
Allison M. McFall, Lakshmi Ganapathi, Mihili P. Gunaratne, Aylur K. Srikrishnan, Conjeevaram K. Vasudevan, Santhanam Anand, Sunil S. Solomon, Shruti H. Mehta, Gregory M. Lucas   +8 more
wiley   +1 more source

Development of a Nurse Practitioner-Directed Buprenorphine Diversion Prevention Protocol in Primary Care

, 2021
BACKGROUND: In the effort to increase access to buprenorphine during the worldwide opioid epidemic, primary care providers are on the frontline in treating opioid addiction in primary care settings.
Brown, Shameka.
core   +1 more source

Buprenorphine, methadone, and morphine treatment during pregnancy: behavioral effects on the offspring in rats

, 2015
Hwei-Hsien Chen,1,2,* Yao-Chang Chiang,3,4,* Zung Fan Yuan,5,6 Chung-Chih Kuo,5,6 Mei-Dan Lai,2 Tsai-Wei Hung,1 Ing-kang Ho,1,3,4 Shao-Tsu Chen2,7 1Center for Neuropsychiatric Research, National Health Research Institutes, Miaoli County, Taiwan; 2Master
Chiang YC, Ho IK, Kuo CC, Lai MD, Yuan ZF, Hung TW, Chen ST, Chen HH   +7 more
core  

Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review

Addiction, EarlyView.
Abstract Background and aims This is the first systematic review of the extant literature on all major psychedelic‐assisted treatment for alcohol use disorder (AUD), tobacco use disorder (TUD) and other substance use disorders (SUD). We aimed to summarise the evidence for efficacy of psychedelic‐assisted treatment for AUD, TUD, and SUD; to evaluate its
Theodore Piper, Francesca Small, Sam Brown, Michael Kelleher, Luke Mitcheson, James Rucker, Allan H. Young, John Marsden   +7 more
wiley   +1 more source

Advances in the delivery of buprenorphine for opioid dependence

, 2017
Richard N Rosenthal,1 Viral V Goradia2 1Department of Psychiatry, Addiction Institute at Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, 2Department of Psychiatry, Upstate Medical University, Syracuse, NY, USA Abstract: Opioid use ...
Rosenthal RN, Goradia VV
core  

5‐Methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive ...
John Marsden, Michael Kelleher, Fiona Dunbar, Anna O. Ermakova, Luke Mitcheson, Claire Roberts, James J. Rucker, Gemma Scott, Ivan Saeger, Francesca Small, Mathieu Seynaeve   +10 more
wiley   +1 more source

Subst Use Misuse [PDF]

Background:Expanding access to medications to treat opioid use disorder (OUD), such as buprenorphine, is an evidence-based response to the mounting drug overdose crisis.

core  

Theorizing causality: A qualitative study of xylazine‐related wound diversity and perceived etiology among people who inject drugs

Addiction, EarlyView.
Abstract Background and aims Incidence and severity of opioid‐associated skin and soft‐tissue infections, often requiring intensive and costly medical care, have increased substantially since the emergence of xylazine in the US drug supply. Although progress has been made in clinical and harm reduction recommendations for treating xylazine‐related ...
Danielle German, Kelci Villarroel, Meredith Denney, Adrian Guta, Julie Evans, Jason Bienert, Alex Fidler, Kim Ashburn, Zach Kosinski, Becky L. Genberg   +9 more
wiley   +1 more source

Predicting buprenorphine adherence among patients with opioid use disorder in primary care settings

BMC Primary Care
Background Medications for opioid use disorder (MOUD), including buprenorphine, are effective treatments for opioid use disorder (OUD) and reduce risk for overdose and death.
Stephanie A. Hooker, Colleen Starkey, Gavin Bart, Rebecca C. Rossom, Sheryl Kane, Anthony W. Olson   +5 more
doaj   +1 more source